Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity

[1]  A. Folgori,et al.  Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates , 2015, Molecular therapy. Methods & clinical development.

[2]  R. Jackson,et al.  Different HIV pox viral vector-based vaccines and adjuvants can induce unique antigen presenting cells that modulate CD8 T cell avidity. , 2014, Virology.

[3]  C. Guzmán,et al.  Intranasal formulations: promising strategy to deliver vaccines , 2014, Expert opinion on drug delivery.

[4]  B. Lidbury,et al.  Use of an In Vivo FTA Assay to Assess the Magnitude, Functional Avidity and Epitope Variant Cross-Reactivity of T Cell Responses Following HIV-1 Recombinant Poxvirus Vaccination , 2014, PloS one.

[5]  B. Moss,et al.  A Novel Mode of Poxvirus Superinfection Exclusion That Prevents Fusion of the Lipid Bilayers of Viral and Cellular Membranes , 2014, Journal of Virology.

[6]  N. Michael,et al.  The Canarypox Virus Vector ALVAC Induces Distinct Cytokine Responses Compared to the Vaccinia Virus-Based Vectors MVA and NYVAC in Rhesus Monkeys , 2013, Journal of Virology.

[7]  F. Granucci,et al.  Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain , 2013, Virus research.

[8]  F. Bihl,et al.  Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells , 2013, Mucosal Immunology.

[9]  M. Bissa,et al.  L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines , 2013, Journal of Translational Medicine.

[10]  K. Chida,et al.  Mouse lung CD103+ and CD11bhigh dendritic cells preferentially induce distinct CD4+ T-cell responses. , 2012, American journal of respiratory cell and molecular biology.

[11]  M. Croft,et al.  CD8 T Cells Are Essential for Recovery from a Respiratory Vaccinia Virus Infection , 2012, The Journal of Immunology.

[12]  N. Lycke.  Recent progress in mucosal vaccine development: potential and limitations , 2012, Nature Reviews Immunology.

[13]  A. Wollenberg,et al.  The Munich outbreak of cutaneous cowpox infection: transmission by infected pet rats. , 2012, Acta dermato-venereologica.

[14]  E. Kroon,et al.  Vaccinia Virus Zoonotic Infection, São Paulo State, Brazil , 2012, Emerging infectious diseases.

[15]  M. Bissa,et al.  Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein , 2011, Journal of Translational Medicine.

[16]  Shengwang Liu,et al.  RESEARCH Open Access , 1996 .

[17]  J. Hooper,et al.  The strategic use of novel smallpox vaccines in the post-eradication world , 2011, Expert review of vaccines.

[18]  D. Marguet,et al.  La(s)t but not least , 2011, Nature Immunology.

[19]  J. Stambas,et al.  A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations. , 2011, Vaccine.

[20]  R. Kurth,et al.  Joint production of prime/boost pairs of Fowlpox Virus and Modified Vaccinia Ankara recombinants carrying the same transgene. , 2011, Journal of virological methods.

[21]  Leonard Moise,et al.  VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. , 2011, Vaccine.

[22]  B. Moss.  Smallpox vaccines: targets of protective immunity , 2011, Immunological reviews.

[23]  C. Zanotto,et al.  Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and immunological comparison. , 2010, Antiviral research.

[24]  R. Eisenberg,et al.  A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge , 2010, Vaccine.

[25]  C. Zanotto,et al.  Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits , 2010, Journal of Translational Medicine.

[26]  J. Arthos,et al.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. , 2010, Vaccine.

[27]  C. Zanotto,et al.  Canarypox and fowlpox viruses as recombinant vaccine vectors: an ultrastructural comparative analysis , 2010, Archives of Virology.

[28]  P. Brandtzaeg.  Function of Mucosa-Associated Lymphoid Tissue in Antibody Formation , 2010, Immunological investigations.

[29]  Shan Lu.  Heterologous prime-boost vaccination. , 2009, Current opinion in immunology.

[30]  C. Zanotto,et al.  Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins. , 2009, Journal of virological methods.

[31]  Geoffrey L. Smith,et al.  Vaccinia virus morphogenesis and dissemination. , 2008, Trends in microbiology.

[32]  R. J. Reed,et al.  US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination. , 2008, Vaccine.

[33]  A. García-Sastre,et al.  Heterologous HA DNA vaccine prime--inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. , 2008, Vaccine.

[34]  A. Artenstein.  New generation smallpox vaccines: a review of preclinical and clinical data , 2008, Reviews in medical virology.

[35]  I. Srivastava,et al.  Dynamics of acute and memory mucosal and systemic immune responses against HIV‐1 envelope following immunizations through single or combinations of mucosal and systemic routes , 2008, Vaccine.

[36]  J. Tournier,et al.  Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. , 2008, Vaccine.

[37]  P. Brandtzaeg.  Induction of secretory immunity and memory at mucosal surfaces. , 2007, Vaccine.

[38]  P. Doherty,et al.  Mucosal HIV-1 pox virus prime-boost immunization induces high-avidity CD8+ T cells with regime-dependent cytokine/granzyme B profiles. , 2007, The Journal of Immunology.

[39]  B. Combadière,et al.  Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells. , 2007, Vaccine.

[40]  P. Doherty,et al.  Mucosal HIV-1 Pox Virus Prime-Boost Immunization Induces High-Avidity CD8+ T Cells with Regime-Dependent Cytokine/Granzyme B Profiles1 , 2007, The Journal of Immunology.

[41]  C. Czerny,et al.  Generalized Fatal Cowpox virus Infection in a Cat with Transmission to a Human Contact Case , 2007, Zoonoses and public health.

[42]  R. Balicer,et al.  An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. , 2007, Vaccine.

[43]  Christiana N. Fogg,et al.  Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges , 2007, Vaccine.

[44]  J. Hooper,et al.  Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge , 2006, Vaccine.

[45]  A. Ramsay,et al.  Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. , 2006, Vaccine.

[46]  G. Karupiah,et al.  Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell Function , 2006, Journal of Virology.

[47]  J. Berzofsky,et al.  Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. , 2006, Blood.

[48]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[49]  K. Reimann,et al.  Smallpox vaccine–induced antibodies are necessary and sufficient for protection against monkeypox virus , 2005, Nature Medicine.

[50]  M. Skinner,et al.  Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry , 2005, Expert review of vaccines.

[51]  G. Poland.  Smallpox vaccines: from first to second to third generation , 2005, The Lancet.

[52]  I. M. Belyakov,et al.  Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8+ T-Cell Peptide Epitope of Vaccinia and Variola Viruses , 2004, Journal of Virology.

[53]  S. Lewis-jones.  Zoonotic poxvirus infections in humans , 2004, Current opinion in infectious diseases.

[54]  J. P. Davis,et al.  The detection of monkeypox in humans in the Western Hemisphere. , 2004, The New England journal of medicine.

[55]  F. Ennis,et al.  Clonal vaccinia virus grown in cell culture as a new smallpox vaccine , 2003, Nature Medicine.

[56]  D. Venzon,et al.  Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. , 2003, Virology.

[57]  J. M. Lane,et al.  Adverse events occurring after smallpox vaccination. , 2003, Seminars in pediatric infectious diseases.

[58]  E. Thompson,et al.  Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates , 2003, Virology.

[59]  M. Law,et al.  The formation and function of extracellular enveloped vaccinia virus. , 2002, The Journal of general virology.

[60]  J. Hickling,et al.  Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer , 1996, Vaccine.

[61]  M. Skinner,et al.  Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. , 1993, Virology.

[62]  P. Earl,et al.  Conserved TAAATG sequence at the transcriptional and translational initiation sites of vaccinia virus late genes deduced by structural and functional analysis of the HindIII H genome fragment , 1986, Journal of virology.

[63]  J. Gordon,et al.  Identification of antigenic determinants by polyclonal and hybridoma antibodies induced during the course of infection by vaccinia virus. , 1986, Virology.

[64]  David Kotlyar.  CD8 T Cells , 2016 .

[65]  Robyn P. Seipp,et al.  MUCOSAL IMMUNITY AND VACCINES , 2013 .

[66]  A. Gerber,et al.  Vaccinia Virus Zoonotic Infection , 2012 .

[67]  N. Sardesai,et al.  Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. , 2011, The Journal of infectious diseases.

[68]  R. Whitley,et al.  Smallpox: a potential agent of bioterrorism. , 2003, Antiviral research.

[69]  R. Pebody,et al.  Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997. , 2001, Emerging infectious diseases.

[70]  A. Radaelli,et al.  Humoral and cell-mediated immunity in rabbits immunized with live non-replicating avipox recombinants expressing the HIV-1SF2 env gene. , 1994, Vaccine.

[71]  A. Radaelli,et al.  Humoral and cell-mediated immunity in rabbits immunized with live non-replicating avipox recombinants expressing the HIV-1SF2env gene , 1994 .

[72]  E. Paoletti,et al.  Potential use of non-replicating vectors as recombinant vaccines. , 1992, Vaccine.